GSK to Showcase Advances in Liver Disease Pipeline at AASLD 2025

GSK to Showcase Advances in Liver Disease Pipeline at AASLD 2025

By, Admin 10 November 2025

GSK plc will present 21 abstracts highlighting advances in its liver disease pipeline at the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting 2025, held in Washington D.C. from 7–11 November. The presentations will feature new data from two late-stage candidates, bepirovirsen and efimosfermin, alongside updates on linerixibat.

Key Highlights

  • Type: Antisense oligonucleotide (ASO) therapy
  • Study: B-Sure Phase II sub-analysis
  • Focus: Evaluating achievement and durability of a functional cure in CHB patients treated with bepirovirsen followed by Peg-IFN therapy.

Efimosfermin: FGF21 Analog for MASH and ALD

  • Type: Once-monthly fibroblast growth factor 21 (FGF21) analog
  • Results: Phase II data show sustained improvements in fibrosis and MASH resolution at 48 weeks for patients with F2/F3 fibrosis.
  • Next Steps: Data support the initiation of ZENITH-1 and ZENITH-2 Phase III trials for moderate and advanced fibrosis due to MASH.
  • ALD Update: Early findings from the ‘990 STARLIGHT’ study indicate favorable safety trends and reduced liver enzyme levels, even with continued alcohol consumption.

Linerixibat: Managing Cholestatic Pruritus

  • Focus: Data reinforce linerixibat’s mechanism of action and safety in cholestatic pruritus, supported by Phase III GLISTEN study results recently published in The Lancet Gastroenterology & Hepatology.
  • Indication: Treatment for primary biliary cholangitis (PBC), an autoimmune liver condition that can lead to liver failure.

GSK’s Broader Liver Disease Strategy

GSK’s hepatology R&D is driven by deep expertise in fibrosis and inflammation, targeting chronic hepatitis B, primary biliary cholangitis, and advanced steatotic liver diseases such as MASH and alcohol-associated liver disease (ALD).

With one in 25 global deaths linked to liver disease, GSK aims to advance immune-driven therapies that can halt or reverse disease progression.

“Our growing liver disease pipeline reflects GSK’s commitment to applying immunology and advanced technologies to address fibro-inflammatory conditions that affect millions worldwide,” the company said in a statement.

About GSK

GSK is a global biopharmaceutical company uniting science, technology, and talent to get ahead of disease together.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!